Intravitreal Adalimumab for the Control of Breakthrough Intraocular Inflammation
- 14 September 2017
- journal article
- research article
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 26 (8) , 1206-1211
Abstract
Purpose: Investigate the efficacy of intravitreal adalimumab in breakthrough panuveitis in patients on systemic adalimumab for more than 3 months. Methods: Retrospective study of patients on systemic adalimumab with breakthrough panuveitis requiring intravitreal adalimumab therapy. Results: Seven eyes of four patients with Adamantiades–Behçet disease panuveitis were included and all were maintained on systemic adalimumab for 7.3 months (range 3–11) with inflammation controlled for 4.1 months (range 2–10) before breakthrough uveitis. The total number of attacks was 13 over 24.5 months (range 12–30). Resolution of attack was defined as return to baseline visual acuity with resolution of inflammatory markers. Three attacks resolved after only one injection and 10 attacks required an average of 2.4 injections (range 2–3). No systemic or ocular complications were noted. Conclusions: Intravitreal adalimumab warrants further investigation as a potentially effective, practical and safe adjunctive therapy for the control of breakthrough inflammation in select patients maintained on systemic adalimumab.Keywords
This publication has 22 references indexed in Scilit:
- Real-time cell analysis – A new method for dynamic, quantitative measurement of infectious viruses and antiserum neutralizing activityJournal of Virological Methods, 2013
- A Comparison Between the Fluocinolone Acetonide (Retisert) and Dexamethasone (Ozurdex) Intravitreal Implants in UveitisJournal of Ocular Pharmacology and Therapeutics, 2013
- A three-centre experience with adalimumab for the treatment of non-infectious uveitisBritish Journal of Ophthalmology, 2012
- Long-Term Effects of Intravitreal Infliximab for Treatment of Sight-Threatening Chronic Noninfectious UveitisJournal of Ocular Pharmacology and Therapeutics, 2012
- Treatment of Experimental Anterior and Intermediate Uveitis by a Dexamethasone Intravitreal ImplantInvestigative Ophthalmology & Visual Science, 2011
- Intravitreal Adalimumab for Refractory Uveitis-Related Macular EdemaOphthalmology, 2010
- Adalimumab Therapy for Refractory Uveitis: A Pilot StudyJournal of Ocular Pharmacology and Therapeutics, 2008
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005
- MODES OF L929 CELL DEATH INDUCED BY TNF-α AND OTHER CYTOTOXIC AGENTSCytokine, 1999
- Tumor Necrosis Factor-α-induced Cell Killing and Activation of Transcription Factor NF-κB Are Uncoupled in L929 CellsJournal of Biological Chemistry, 1998